Market Cap 16.84M
Revenue (ttm) 0.00
Net Income (ttm) -44.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,765,327
Avg Vol 14,877,256
Day's Range N/A - N/A
Shares Out 46.08M
Stochastic %K 31%
Beta 0.52
Analysts Sell
Price Target $4.00

Company Profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort,...

Industry: Biotechnology
Sector: Healthcare
Phone: 608 441 8120
Address:
100 Campus Drive, Florham Park, United States
DM0n3y
DM0n3y Aug. 18 at 7:17 PM
$CLRB Ending the day strong. More eyes on this one for sure.
0 · Reply
MSG8898
MSG8898 Aug. 18 at 7:16 PM
$CLRB gimme 5
0 · Reply
MSG8898
MSG8898 Aug. 18 at 6:58 PM
$CLRB IMO with second line therapy indication and almost ready to file for NDA, I might revise my personal TP to the 18-20 area.
1 · Reply
JLynneB51671
JLynneB51671 Aug. 18 at 6:47 PM
$CLRB It's pushin hard! LFG!!! 🤞🙌🙏🚀🚀🚀
0 · Reply
MSG8898
MSG8898 Aug. 18 at 6:43 PM
$CLRB poised to explode shortly
1 · Reply
JLynneB51671
JLynneB51671 Aug. 18 at 6:12 PM
$CLRB No, seriously... Legit asking. 🤷‍♀️🤦‍♀️
1 · Reply
JLynneB51671
JLynneB51671 Aug. 18 at 1:34 PM
$CLRB Was I dreaming/ imagining that this went above $5 in the wee hours??
0 · Reply
DM0n3y
DM0n3y Aug. 18 at 12:48 PM
$CLRB volume has arrived. Let's RIIIIIIDDDEEEEE
0 · Reply
Jeanvaljean4
Jeanvaljean4 Aug. 18 at 12:21 PM
$CLRB Something strange is happening with this stock. What are these big bullish spikes that last a few minutes?
0 · Reply
JLynneB51671
JLynneB51671 Aug. 18 at 8:57 AM
$CLRB I am!!!
0 · Reply
Latest News on CLRB
Cellectar Announces Plan to Explore Strategic Alternatives

Apr 30, 2025, 8:05 AM EDT - 3 months ago

Cellectar Announces Plan to Explore Strategic Alternatives


Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 12:41 PM EDT - 5 months ago

Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript


DM0n3y
DM0n3y Aug. 18 at 7:17 PM
$CLRB Ending the day strong. More eyes on this one for sure.
0 · Reply
MSG8898
MSG8898 Aug. 18 at 7:16 PM
$CLRB gimme 5
0 · Reply
MSG8898
MSG8898 Aug. 18 at 6:58 PM
$CLRB IMO with second line therapy indication and almost ready to file for NDA, I might revise my personal TP to the 18-20 area.
1 · Reply
JLynneB51671
JLynneB51671 Aug. 18 at 6:47 PM
$CLRB It's pushin hard! LFG!!! 🤞🙌🙏🚀🚀🚀
0 · Reply
MSG8898
MSG8898 Aug. 18 at 6:43 PM
$CLRB poised to explode shortly
1 · Reply
JLynneB51671
JLynneB51671 Aug. 18 at 6:12 PM
$CLRB No, seriously... Legit asking. 🤷‍♀️🤦‍♀️
1 · Reply
JLynneB51671
JLynneB51671 Aug. 18 at 1:34 PM
$CLRB Was I dreaming/ imagining that this went above $5 in the wee hours??
0 · Reply
DM0n3y
DM0n3y Aug. 18 at 12:48 PM
$CLRB volume has arrived. Let's RIIIIIIDDDEEEEE
0 · Reply
Jeanvaljean4
Jeanvaljean4 Aug. 18 at 12:21 PM
$CLRB Something strange is happening with this stock. What are these big bullish spikes that last a few minutes?
0 · Reply
JLynneB51671
JLynneB51671 Aug. 18 at 8:57 AM
$CLRB I am!!!
0 · Reply
stevenryl86
stevenryl86 Aug. 18 at 8:52 AM
$CLRB nobody noticed on lock up expires???
0 · Reply
rat_dog
rat_dog Aug. 18 at 8:19 AM
$CLRB nobodies awake for this?
0 · Reply
MSG8898
MSG8898 Aug. 17 at 8:41 PM
$CLRB the website seems slowly brewing
1 · Reply
szcyxzh
szcyxzh Aug. 17 at 1:18 PM
$CLRB Every event (e.g., strategic realignment, laughable million-dollar-scale fund raising through dilutive warrants) in the CLRB's past 24 months is very, very similar to Unity Bio's path. CLRB's fate, bankrupt or not, will be unveiled by this time next year.
0 · Reply
MSG8898
MSG8898 Aug. 17 at 11:34 AM
$CLRB IMO no doubt that the CMA application will go through the CHMP, that's why they stated late Q3 (CHMP will be 15-18 September) or early Q4 (CHMP will be 13-16 October), with decisions out on the very next Friday. That timeframe would IMO also perfectly fit the LLM Congress to be held in NY on the 14-17 October. On the other hand this would possibly push the partnership announcement a bit further, especially for WW rights, not necessarily so if for the US market alone, considering they aim to file the NDA in between late 25 or early 26, and I bet the potential partner would want to go through the application before it gets filed. So to me, best case scenario is US partner right away and other territories shortly thereafter, or WW partner in mid October at the latest. If they feel the need to speed up things, they could release 12 months results right away, discussing them later on through the NY Conference. That would speed up partnering and EMA discussions a bit, IMO.
1 · Reply
ObsOlet
ObsOlet Aug. 17 at 7:35 AM
$CLRB Oppenheimer Maintains Hold Rating on Cellectar Biosciences with $18.00 Average Price Target https://www.ainvest.com/news/oppenheimer-maintains-hold-rating-cellectar-biosciences-18-00-average-price-target-2508/
0 · Reply
MSG8898
MSG8898 Aug. 16 at 7:19 PM
$CLRB and don't forget the closing session where any big pharma will be looking for final tips
0 · Reply
MSG8898
MSG8898 Aug. 16 at 7:18 PM
$CLRB I believe this will be it
0 · Reply
MicroCapValue
MicroCapValue Aug. 16 at 5:53 PM
$CLRB good chance the new iopofosine I 131 data (12-month follow-up all pts + subset BTKi failures) will be presented at ASH, the biggest annual blood cancer/disorder medical conference of the year and they presented there last year. If regular abstract, would be available and announced on 11/3 or 12/1 if late-breaking and data should continue to impress and be way better than current options... https://www.hematology.org/meetings/annual-meeting/abstracts All points to exciting weeks/months ahead with likely partnership(s) to support start of confirmatory P3 trial, clinical data updates/presentation (could also get update on pediatric brain cancer trial) and hopefully accelerated US/EU approval filings by late-25/early-26. All this and less than 3.2 million shares outstanding (per 10-Q filing on 8/14) and funded into 2Q26 which provides plenty of time to deliver on partner(s) for non-dilutive funding as the process is well underway with multiple parties per update last week with OpCo engaged since late April.
2 · Reply
MSG8898
MSG8898 Aug. 16 at 1:26 PM
$CLRB went through the CC and Q&A again and dudes, this will fly real soon. Second line therapy about to file a NDA for, and finalizing the protocol for pivot trial that will allow the submission. Full data of P2 to be released soon and talks with the Ema ongoing. To da moooon!
0 · Reply
transamlover
transamlover Aug. 16 at 12:49 PM
0 · Reply
ObsOlet
ObsOlet Aug. 16 at 12:48 PM
$CLRB My favorite part of the conference calls: Operator: [Operator Instructions] And the next question comes from Ted Tenthoff from Piper Sandler. Edward Andrew Tenthoff: "Congratulations. This is a really meaningful update this series of events from breakthrough designation to the 12-month data and then the commitment and decision to move into the second-line confirmatory trial, all positioning for an NDA for accelerated approval, really exciting stuff......"
0 · Reply